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A B S T R A C T
The signaling of reactive oxygen species (ROS) is essential for the maintenance of normal cellular function.
However, whether and how ROS regulate stem cells are unclear. Here, we demonstrate that, in transgenic mice
expressing the human manganese superoxide dismutase (MnSOD) gene, a scavenger of ROS in mitochondria,
the number and function of mouse hematopoietic stem/progenitor cells (HSPC) under physiological conditions
are enhanced. Importantly, giving MnTnBuOE-2-PyP5+(MnP), a redox- active MnSOD mimetic, to mouse
primary bone marrow cells or to C57B/L6 mice significantly enhances the number of HSPCs. Mechanistically,
MnP reduces superoxide to hydrogen peroxide, which activates intracellular Nrf2 signaling leading to the
induction of antioxidant enzymes, including MnSOD and catalase, and mitochondrial uncoupling protein 3. The
results reveal a novel role of ROS signaling in regulating stem cell function, and suggest a possible beneficial
effect of MnP in treating pathological bone marrow cell loss and in increasing stem cell population for bone
marrow transplantation.
1. Introduction
Hematopoietic stem cells (HSCs) have the capacity for self-renewal
and multilineage differentiation. It is well-documented that HSCs
reside in a hypoxia niche [1] and have a low level of reactive oxygen
species (ROS) compared with their mature progeny [2,3]. Hypoxia
plays critical roles in maintaining stem cell quiescence and stemness
[4,5]. Life-long measurements of local oxygen tension (pO2) in the
bone marrow of living mice show that the absolute pO2 of bone marrow
is < 32 mm Hg and that the lowest pO2 in the deeper peri-sinusoidal
regions where HSCs reside is only 9.9 mm Hg [6]. In adult stem cells
such as hematopoietic stem cells or mesenchymal stem cells, hypoxia
prolongs the lifespan of stem cells, increases their self-renewal
capacity, and reduces differentiation in culture [3,7]. Culturing bone
marrow cells with 1–3% O2 enhances HSCs expansion and engraftment
compared to the 21% O2 counterparts [8,9].
The roles of mitochondria and reactive oxygen species (ROS) in
regulating stem cell fate are crucial and complex. It is generally thought
that stem cell self-renewal relies primarily on glycolysis and the
pentose phosphate pathway, and also on a deliberate suppression of
oxidative phosphorylation (OXPHOS) [10]. Some of the experimental
evidence in support of this concept includes: 1) Direct measurement of
the incorporation of 13C from glucose into lactate indicates that long
term hematopoietic stem cells (LT-HSCs) rely on anaerobic glycolysis,
and have lower rates of oxygen consumption and lower ATP levels than
other cells in bone marrow [11]; 2) Forced activation of OXPHOS leads
to loss of stem cell properties and increased differentiation and
apoptosis [12]; 3) Inhibition of complex III of the mitochondrial
respiratory chain using antimycin A or myxothiazol promotes human
ESC self-renewal and pluripotency [13]; 4) Genetic ablation of
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Hypoxia-inducible factors (HIFs), which causes an increase in ROS and
activation of OXPHOS, results in the loss of quiescence and the self-
renewal properties of hematopoietic stem cells (HSCs) [14]; 5) c-kit-
positive stem/progenitor cells show lower basic levels and faster
clearance of accumulated intracellular ROS, and higher resistance to
oxidative stress compared to c-kit-negative mature mononuclear cells
[15]. However, whether and how the subtle changes in mitochondrial
function and ROS production modulate stem cell function and survival
remain unknown.
Mitochondria are the primary site of superoxide radical generation.
The superoxide dismutase (SOD) family of enzymes catalyzes the
dismutation of superoxide anion (O2•-) radical to hydrogen peroxide
(H2O2) and molecular oxygen (O2). This family of enzymes is com-
prised of MnSOD, located in the mitochondrial matrix, and Cu, ZnSOD,
located in the mitochondrial intermembrane space, cytosol and extra-
cellular space. The presence of MnSOD is essential for the survival of
all aerobic organisms from bacteria to humans [16,17]. Since MnSOD
has a critical role in controlling ROS generated in mitochondria, we
examined the effect of MnSOD on hemapoietic stem and progenitor
cells (HSPCs) in transgenic mice expressing the human MnSOD gene.
We found that overexpressing MnSOD in the mitochondria of trans-
genic mice enlarges the pool of HSPCs compared to the result for wild-
type littermates. To further explore the impact of ROS on bone marrow
cells, we tested a synthetic compound, Mn(III) meso-tetrakis(N-n-
butoxyethyl-pyridinium-2yl)porphyrin, MnTnBuOE-2-PyP5+, BMX-
001 (MnP), an MnSOD mimetic that catalyzes superoxide dismutation
in a SOD-like manner. The chemistry and biology of the family of Mn-
containing porphyrin have been reviewed extensively [18]. The pro-
tective effects of SOD mimetics in the normal cells of a number of
animal models have been reported. For instance, in normal tissues of
animal models, MnP and an earlier analog, MnTE-2-
PyP5+(AEOL10113, BMX-010), were found to be effective radiopro-
tectants of radiation-induced injuries of salivary gland and mouth
mucosa [19], bone marrow [20], brain [21], rectum [22] and urogenital
tissues [23]. Consequently, several SOD mimetics are being tested in
Phase I/II clinical trials for protection of normal tissues against injury
from ROS-generating therapeutics including ionizing radiation.
MnP, the newest generation of SOD mimetic, is optimized for
catalytic potency and safety/toxicity [24]. It is preferentially localized
in the mitochondria and has been shown to have very limited side
effects in animal models [18]. In the present study, we report that MnP
treatment of freshly isolated mouse bone marrow cells and mice
increases the number of bone marrow HSPC cells and improves the
function of long-term engraftment and multi-lineage differentiation of
the HSCs. The results reveal a novel aspect of ROS regulation in stem
cell function and strengthen the clinical potential of MnP.
2. Materials and methods
2.1. Reagents, treatment and animal study
MnP was synthesized and characterized by Dr. Ines Batinic-Haberle
and her colleagues (Duke University School of Medicine, Durham, NC,
USA). In vitro treatment of MnP was done on freshly isolated bone
marrow cells from 9 to 12 weeks-old C57BL/6 female mice with either
H2O (2–5 μl/ml of culture media as vehicle depending on the
concentration of MnP used) or 5–20 μM of MnP for 1–16 h at 37 °C
in 5% O2 incubator. In vivo treatment was performed using in-house
bred, 9–12 weeks-old, female C57BL/6 mice. The mice were treated
with either saline (vehicle) or MnP at 2 mg/kg, 3 times/week sub-
cutaneously (s.c.) for up to 60 days. All animal studies were conducted
using procedures approved by Institutional Animal Care in accordance
with the NIH Guide for the Care and Use of Laboratory Animals.
2.2. Immunofluorescent staining of bone marrow cells
Bone marrow cell isolation, immune-staining and flow cytometry
were performed as described [25]. In brief, cells were extracted from
two femurs and tibias of mouse. RBCs were lysed to get bone marrow
nucleated cells (BMNCs). The BMNCs were stained with the following
antibodies: Biotin-conjugated lineage markers, including CD5 (Cat#
553019), CD8a (Cat# 553029), CD45R/B220 (Cat# 553086), CD11b/
Mac-1 (Cat# 553309), Ly-6G/Gr-1 (Cat# 553125), TER119/Ly-76
(Cat# 553672) followed by Streptavidin-conjugated secondary fluor-
escent antibody (Cat# 554063) and stem cell–specific markers, PE or
PEcy7-conjugated Ly-6A/E (Cat# 553336, 558162) and APC or Percp
Cy5.5-conjugated CD117 (Cat# 553356, 560557). All antibodies were
purchased from Pharmingen. Flow cytometric analysis was performed
on FACS Calibur flow cytometer (Becton Dickinson, San Jose, CA,
USA).
2.3. Colony-forming cell assay (CFC) and cobblestone area-forming
cell (CAFC) assays
The CFC assay was described previously [25]. Briefly, freshly
isolated total bone marrow cells were suspended in Methocult GF
M3434 methylcellulose medium (StemCell Technologies, Vancouver,
B.C., Canada). Triplicate cultures were set up for each specimen
according to the manufacturer's instructions. After 14 days of culture,
the total colony- forming unit (CFU) were counted.
The CAFC assay was described previously [25]. Briefly, a monolayer
of FBMD-1 stromal cells was plated in 96-well plates and grown to
confluent; whole bone marrow cells were seeded at 81,000, 27,000,
9000, 3000, 1000 or 333 cells per well in CAFC medium (Iscove's MDM
supplemented with 20% horse serum, 10−5 M hydrocortisone, 10−5 M
2-mercaptoethanol, 100 U/ml penicillin, and 100 μg/ml streptomycin).
Twenty replicate wells per cell number were counted. The frequency of
CAFC was determined on days 7, 14, 21, 28 and 35. Wells were scored
positive if at least one phase dark hematopoietic clone (containing five
or more cells) was seen. The frequencies of CAFCs were calculated
using the L-Calc program (StemCell Technologies).
2.4. Serial bone marrow transplantations (BMT)
One million bone marrow cells (CD45.2) treated either with 20 μM
MnP for 16 h in vitro or with MnP in vivo (2 mg/kg, 3 times/week s.c.
for 60 days) were mixed with 106 of helper cells (CD45.1) in 200ul PBS,
and the mix was injected intravenously into lethally irradiated (9 Gy)
CD45.1 recipient mice (n=6 for each control or MnP treatment). At 16-
week post the first BMT, total bone marrow cells were isolated and
analyzed for CD45.2 positive stem and progenitor cell frequency, and
10×106 cells/mouse were transplanted to another CD45.1 mouse (n=6)
as secondary BMT. The third BMT was performed with 10×106 cells/
mouse of total bone marrow cells from the secondary bone marrow
transplanted mouse at week 16 post-secondary BMT (n=6 for treat-
ment and control). CD45.2 positive T cell, B cell, granulocytes and
macrophages of peripheral blood were analyzed every four weeks post
each BMT to check transplanted cell engraftment as described pre-
viously [25]. Peripheral blood cell counts were performed at the end of
each 16-week BMT.
2.5. Quantitative real-time PCR (qPCR)
Total RNA was isolated from approximately 5×104 LSK (lineage
negative, c-kit and Sca1 positive) cells using RNeasy Micro Kit (Qiagen,
Cat# 74004). First-strand cDNA was reverse-transcribed and then
preamplified with the Transcriptor first strand cDNA synthesis kit and
cDNA Pre-Amp Master mix (Roche, Cat# 04379012001,
06720455001), respectively. Pre-amplification for the tested genes
was 12 cycles. qPCR was performed with LightCycler 480 Probes
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Master system (Roche, Cat# 04707494001). All experiments were
performed following manufacturers’ instructions. Actin and 28 S were
used as endogenous controls for normalization of gene expression.
2.6. Mitochondrial function and ATP production measurement
Oxygen consumption in cells was determined using the Seahorse
Extracellular Flux (XF-96) analyzer (Seahorse Bioscience, Chicopee,
MA, USA). Bone marrow cells were isolated and treated with MnP at
20 μM for 2 h. The cells were then harvested, antibody-labeled and flow
cytometry sorted in ice or at 4 °C. 200,000 LSK cells in triplicate for
treatment or control were cytospinned to the bottom of a XF96 Tissue
Culture Plate (Seahorse Bioscience) coated with BD Cell-Tak Cell
Adhesive. OCR was measured three times and plotted as a function
of cells under the basal condition followed by the sequential addition of
oligomycin (1 μg/ml), FCCP (1 μM), or antimycin (2 μM) and rotenone
(1 μM) for the ATP-linked, maximum, and reserve capacities of oxygen
consumption, respectively.
BMNCs were isolated from mice (n=6). The cells were treated with
either vehicle or 20 μM MnP for 1 h. at 37 °C, stained and sorted for
LSK and MyPro (Lineage negative, c-kit positive, Sca1 negative) cells in
ice or at 4 °C. Sorted cells (3×104) were lysed, and intracellular ATP
activity was measured using the Luciferase ATP Bioluminescent
somatic cell assay kit (Sigma, Cat# FLASC) following the manufac-
turer's instructions.
2.7. Dichlorofluorescein (DCF) and GSH/GSSH analyses
DCF assays were performed as previously described [26]. Briefly,
after treatment, BMNCs were immune-stained and incubated with
10 μg/ml of carboxy-H2DCFDA (sensitive to oxidation, Invitrogen) or
1 μg/ml of oxidized carboxy-DCFDA (DCFDA, insensitive to oxidation,
Invitrogen) in PBS /0.5% FBS at 37 °C for 20 min. The fluorescence in
cells preloaded with carboxy-H2DCFDA was normalized to that in cells
preloaded with DCFDA (ratio of H2DCFDA/DCFDA) to control for the
cell number and dye uptake. The ester cleavage differences between
different treatment groups were measured.
Sample extraction and LC-MS/MS analysis of GSH and GSSG have
been previously described [27]. In brief, BMNCs treated with either
vehicle or MnP were centrifuged at 1300 rpm for 5 min. Cells were
resuspended in 75 μl of extraction buffer (2% TCA, 1 mM EDTA),
incubated on ice for 15 min, then vortexed for 30 s and incubated on
ice for an additional 15 min. Cellular debris was then pelleted by
centrifugation at 4000×g for 10 min. Sample extracts were then
collected and pH was adjusted to 2.0 prior to LC-MS/MS analysis as
previously described [27].
2.8. Transcription factor (TF) profiling and western blots
BMNCs were obtained from C57B/L6 mice (5 mice/group). Cells
were treated with either vehicle or 20 μM MnP for 1 h at 37 °C,
immunostained and flow cytometry sorted for lineage marker negative
(Lin-) and CD117 (ckit) positive cells (LK) at 4 °C. Nuclear extractions
were isolated with Nuclear extraction kit by Signosis (Cat SK-0001)
following manufacturer's protocol. TF profiling was performed using
the Oxidative stress TF activation profiling plate array (Signosis Cat#
FA-1005) by following the manufacturer's instructions. Triplicate wells
with the nuclear extracts from 3 groups of mice were used for the TF
profiling.
Western blots were prepared using the same protocol as described
previously [26]. Briefly, BMNCs were treated with vehicle or 20 μM of
MnP for 16 h at 37 °C, harvested, stained and flow cytometry sorted for
LK cells. Ten micrograms of total protein from each cell lysate were
loaded on SDS-PAGE and blotted with various antibodies.
2.9. Statistical analysis
The TF profiling was done at n=3 group of 5 mice. Other
experiments were done with samples n≥6. The experiments were
conducted at least three times to verify the reproducibility of the
findings except for the TF profiling and serial BMT. Statistical analyses
were carried out with Statistical Analysis System software (SAS
Institute, Cary, NC, USA) and P values were calculated using the
Student's t-test.
3. Results
3.1. MnP promotes the expansion of mouse bone marrow HSPCs
We have previously generated transgenic mice expressing the
human MnSOD gene and performed extensive characterization of the
animals [28]. We have verified that MnSOD is located in the matrix of
mitochondria and that there is no significant change in other anti-
oxidant enzymes or small molecular weight antioxidants that may
impact the cellular redox state. Bone marrow cell frequency analysis of
transgenic mice expressing human MnSOD shows that the LSK cells
[lineage negative (Lin-) / Ly-6A/E positive (Sca1+) / c-kit positive (c-
kit+)] bone marrow stem/progenitor cells and myeloid progenitor cells
(MyPro) (Lin-, c-kit+ and Scal1-) were significantly increased by ~40%
and 18% respectively compared to the wild-type (wt) littermates
(Fig. 1B upper and middle panels), whereas the Lin+ mature cells
have no change (Fig. 1B lower panel). We examined the effect of MnP
on bone marrow cells since MnP is designed to especially mimic
MnSOD. We treated freshly isolated mouse BMNCs with 5, 10, 20 or
25 μM of MnP for 16 h under 5% O2 culturing conditions. The results
show that at 10–25 μM, MnP significantly increased LSK frequency
(data not shown). At 20 μMMnP, the increase of LSK was about ~30%,
but there was no significant influence on MyPro and Lin+ cells (Fig. 1D
upper, middle and lower panels, respectively). To determine if treat-
ment with MnP in vivo could also increase LSK population in mouse
bone marrow, we injected MnP at 2 mg/kg s.c., 3 times/week into
C57B/L6 mice for 60 days. The results show that MnP given in vivo
increased LSK cells by ~30% and MyPro by ~20% (Fig. 1C upper and
middle panels), without any significant effect on Lin+ cells (Fig. 1C
lower panel). We additionally performed peripheral blood counts on
the 60-day MnP-treated mice and the wild- type and MnSOD trans-
genic mice. The peripheral blood counts show no significant change
(data not shown). Thus, MnP or overexpressing MnSOD in mice
enlarges the HSPC pool of bone marrow without altering the mature
cell population, suggesting that mature cells are tightly regulated under
normal physiological conditions.
To further examine the functional change of the increased stem and
progenitor cells after MnP treatment, we performed CAFC and CFU
assays, which measure HSC and progenitor clonogenic functions,
respectively. At day 35 of CAFC assays, the approximate increases of
cobble stone colonies for the bone marrow cells from MnSOD
transgenic mice compared to wild- type controls and for MnP in vivo-
and in vitro- treated bone marrow cells were 30%, 50% and 18%
respectively (Fig. 2A, i, ii, iii). The results suggest that bone marrow
stem cells maintain normal or increased clonogenic function. Using a
MethoCult-based CFC assay, we tested the progenitor cell colony
forming function. The total colony forming units (CFU) at day 14 were
increased by about 23%, 45% and 18% for the bone marrow cells from
MnSOD transgenic mice and MnP in in vivo- and in vitro- treated
compare to controls, respectively (Fig. 2B, i, ii, iii). The results are
consistent with the slightly increased frequency of MyPro cells seen
from Flow cytometry analysis in the 60-day MnP-treated and MnSOD
transgenic mice. Interestingly, the total CFUs were also increased in the
16-hr in vitro MnP- treated cells. The results suggest a normal or
enhanced function of the progenitor cells.
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3.2. MnP enhances long-term stem cell engraftment and multilineage
differentiation after serial bone marrow transplantation (BMT)
The purpose of serial BMT is to test the self-renewal and multi-
lineage differentiation capabilities of HSCs. To examine the long-term
engraftment and repopulation capacity of stem cells after treatment
with MnP, we performed three rounds of serial bone marrow trans-
plantations. 106 of total bone marrow cells (CD45.2) treated with either
vehicle or MnP in vitro for 16 h or in vivo for 60 days and 106 of helper
cells (CD45.1) were used as donor cells. The donor cells were bone
marrow transplanted to lethally irradiated recipient mice (CD45.1).
Peripheral blood samples were collected and analyzed four times, at
four-week intervals, for the donor cell engraftment. Animals were
euthanized at 16 weeks, and the donor- derived (CD45.2) peripheral
blood as well as bone marrow cells were analyzed by flow cytometry. At
the same time, 107 total bone marrow cells from the first or second
transplanted animal were used for the second or the third BMT,
respectively. Three rounds of BMT at 16- week intervals (for a total
of 48 weeks) were performed. Our results show that the LSK cells
slightly increased at 16 weeks post the first BMT with no significance
(Fig. 3A (i) and B (i)), and increased by 20% and 17% respectively when
in vivo- treated BM cells were used as donor cells at the end of the
second and the third BMTs (Fig. 3A (ii), (iii)). When using in vitro
treated bone marrow cells as donors the increases were 39% at the end
of second BMT and 33% at the end of third BMT respectively (Fig. 3B
(ii), (iii)). We also flow-cytometry analyzed CD45.2 positive T-cell, B-
cell and Granulocytes from bone marrow of each BMT at the end of 16
weeks and found no significant difference between control and treated
cells. The results at 48 weeks are shown in Supplemental Fig. 1.
Peripheral blood counts every four weeks during the three rounds of
BMT show no significant change compared to the BMT with control-
treated cells (data not shown) suggesting that MnP can specifically
increase HSC function without affecting downstream progenies. Since
long-term engraftment and multilineage development are the gold
standard of stem cell function, the results suggest that MnP enhances
the function of bone marrow stem cells.
3.3. MnP reduces mitochondrial oxidative phosphorylation and
intracellular ATP production in bone marrow cells
Stem cells rely primarily on glycolysis and the pentose phosphate
pathway, with a deliberate suppression of oxidative phosphorylation
(OXPHOS) [10] for their energy demand and maintenance of stemness.
Since the cellular localization of MnP is mainly in the mitochondria, we
next checked the function of mitochondria and the energy production
in bone marrow cells after MnP treatment. Freshly isolated BMNCs
were treated with vehicle or 20 μM MnP in 5% O2 incubator for 2 h.
LSK cells were flow cytometry sorted at < 4 °C. Triplicate 200,000 LSK
cells were cytospinned to the bottom of the Seahorse microplate, and a
Seahorse XF analyzer was used to measure oxygen consumption rate
(OCR). Fig. 4A and B indicates that basal OCR, a measure of total
oxygen consumption at basal conditions, was reduced by 10% in LSK
cells after MnP treatment. Oligomycin inhibits ATP synthase in
complex V in the electron transport chain (ETC). Upon Oligomycin
application, the ATP linked that represents the oxygen consumption
linked to ATP synthesis through OXPHOS was reduced by 35%. The
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Fig. 1. LSK & MyPro cell frequency is increased in MnSOD transgenic mice and the cells treated with MnP in vitro and in vivo. A. The gating strategy of flow cytometry analysis. B.
Bone marrow cells were isolated from wild- type (SOD WT) or MnSOD transgenic (SODTgH) mice. C. C57B/L6 mice (n=8) were injected (i.c.) with vehicle (Saline) or MnP (MnP) at
2 mg/kg, 3 times/week for 60 days. D. Freshly isolated bone marrow cells from C57B/L6 mice (n > 6) were treated with vehicle (H2O) or 20 μMMnP (MnP) for 16 h in vitro. Cells were
immunostained and flow cytometry analyzed. Upper panels are the percentage of LSK cells (lin- Sca1+ c-kit+) in the total bone marrow nucleated cells (BMNCs). The middle and lower
panels are MyPro (lin- Sca1- c-kit+) and lineage positive (Lin+) cells, respectively. *P < 0.05 was considered significant (Student's t-test). *P < 0.05; **P < 0.01; ***P < 0.001 as compared
with controls for this and the following figures. Data represent the mean+SD of at least three independent experiments.
Y. Zhao et al. Redox Biology 12 (2017) 129–138
132
injection of FCCP decouples ATP synthesis and hydrogen ion transport
in ETC, leading to rapid consumption of energy without the generation
of ATP, and is used to measure the maximal oxygen consumption
capacity of mitochondria under stress conditions. We observed that
MnP treatment reduced the maximal capacity by 33% in LSK cells.
Rotenone and antimycin are used to inhibit the function of complexes I
and III, respectively, leading to complete inhibition of ETC. The reserve
capacity is calculated as the difference between maximal OCR and basal
OCR. Our result shows that the mitochondrial reserve capacity was
reduced by nearly 44% after MnP treatment (Fig. 4A & B). Thus, MnP-
treated bone marrow HSPC cells, at early time, have a reduced level of
mitochondrial oxygen consumption, which suggests reduction of
mitochondrial function and is consistent with an enhanced stem cell
population.
To further examine the metabolic change caused by MnP treatment,
we measured total cellular ATP levels by using a Luciferase ATP
Bioluminescent somatic cell assay kit. To observe early changes, mouse
BMNCs were isolated, treated with vehicle or 20 μM MnP in a 5% O2
incubator for 1 h. The intracellular ATP level in cell lysate from 3×104
LSK or MyPro cells were determined with multiple repetitions. As
shown in Fig. 4C, the total ATP level was reduced by 45% in LSK cells
and 20% in MyPro cells, which is consistent with the reduction of
OXPHOS. Collectively, MnP directly reduced mitochondrial OXPHOS
function in HSPCs, and these results are consistent with the notion that
the reduction of mitochondrial OXPHOS and ATP production facil-
itates the maintenance of stem cell pool and function. Additionally, the
difference of ATP reduction in more primitive LSK compare to MyPro
caused by MnP treatment suggests that either LSKs are more sensitive
to MnP or have stronger mechanism to reduce their mitochondrial
function.
3.4. MnP acts as a mild pro-oxidant but does not affect redox
homeostasis in HSPCs
It is generally thought that elevated ROS favors stem cell differ-
entiation and reduces cell quiescence. MnP, as an MnSOD mimetic, is
developed to scavenge O2
•−. Therefore, we next examined the intracel-
lular ROS level of the freshly isolated BMNCs after incubation with
20 μM MnP or vehicle for 2 h. The cells were immunostained at 4 °C
and labeled with 10 μg/ml of carboxy-H2DCFDA (sensitive to oxida-
tion) or 1 μg/ml of DCFDA (insensitive to oxidation) for 20 min at
37 °C. Surprisingly, we found that the normalized DCF fluorescence,
expressed as mean fluorescence intensity (MFI), in the MnP-treated
Lin+, MyPro and LSK cells was elevated by 26%, 33% and 35%,
respectively, compared to the vehicle treatment (Fig. 5A). The addition
of catalase (CAT) completely inhibited the increase of the DCF signal
suggesting that the elevated ROS is superoxide-derived H2O2. We also
examined ROS status in the BM cells from 60-day treated mice and
MnSOD transgenic mice. The H2DCFDA/DCFDA level in three cell
types has no significant difference between saline and MnP treatments,
and MnSOD transgenic and wild- type mice (Fig. 5B & C). Based on
these results we hypothesized that MnP might act as a mild pro-oxidant
elevating H2O2 in bone marrow cells. The ROS elevation only occurred
at the 2 h in vitro treatment and not in the in vivo treatment suggesting
that the pro-oxidative effect of MnP is transient and might be overcome
by adaptive antioxidative responses.
Acting as antioxidants as well as potential pro-oxidant generators,
SOD mimetics convert O2•- to H2O2. Thus, a SOD mimetic functions as
a real antioxidant only when its product is removed rapidly by a
catalase or peroxidase system. A normal cell is well equipped with
multiple H2O2-removing systems such as catalases, glutathione perox-
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Fig. 2. MnP promotes clonogenic function of HSCs and HSPCs. A. The clonogenic function of HSCs was measured at day 35 with CAFC assay. B. The HSPC clonogenic function was
determined by counting the total colony forming units per 10,000 BMNCs in CFC assay at day 14. (i) Cells isolated from MnSOD wild- type (WT) and transgenic mice (SOD TgH). (ii)
MnP 60-day in vivo treatment. (iii) MnP 16 h in vitro treatment. (n > =3). Data represent the mean+SD of three independent experiments.
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idases, glutathione transferases, peroxyredoxins and thioredoxins.
Unlike many reports that have stated that an increase in ROS results
in the subsequent loss of quiescence and the self-renewal properties of
HSCs, our results show that MnP behaves like a mild pro-oxidant in
hematopoietic cells, but increases HSPC pool and stem cell function.
We next examined the redox balance of LSK cells by determining the
ratio of 2x GSH/GSSG, as the glutathione redox couple is the major
indicator of cellular redox state. Freshly isolated BMNCs were treated
with either vehicle or 20 μM MnP for 2 h or 16 h, immunostained and
flow cytometry sorted at 4 °C. Twenty thousand LSK cells were used for
simultaneous analysis of GSH and GSSG by the sensitive LS/MS
method we recently developed [27]. The results show no change at
2 h treatment (Fig. 5D left panel) and a slightly reduced status at 16 h
with MnP in vitro treatment (Fig. 5D right panel). The result of the 2x
GSH/GSSG ratio on MyPro cells treated with vehicle and MnP shows
no difference as well (data not shown). These results support our
hypothesis that the adaptive responses were able to maintain normal
intracellular redox balance.
To further specify the defense capability of ROS in different lineages
of the cells, we investigated the redox status of the LSK and MyPro
cells. Freshly isolated, stained and flow cytometry- sorted 20,000 LSK
or MyPro cells were used. The 2x GSH/GSSG ratio was 2.5x higher in
LSK cells compared to that in the MyPro cells (Fig. 5E). The result
suggests that LSK cells are in a more reduced status than progenitor
cells are.
In the next experiment, we wanted to investigate the capacity
difference of scavenging H2O2 in different lineage cells. In these
experiments, the freshly isolated BMNCs cells were immunostained,
incubated with H2DCFDA or DCFDA for 20 min, exposed to various
concentrations of H2O2 for 15 min at 37 °C, washed, and flow
cytometry analyzed. At the concentration of 50 μMH2O2, the cellular
ROS increased 9.3x, 10.6x and 27x for LSK, MyPro and Lin+ cells,
respectively. At 100 μMH2O2, ROS increased 14.1x, 25.3x and 49.5x
for LSK, MyPro and Lin+ cells, respectively (Fig. 5F). These results
further confirm that LSK cells have a higher capacity to clear H2O2
compared to mature cells. These results suggest that the transient and
mild elevation of intracellular ROS caused by MnP can be overcome by
the strong intracellular antioxidant defense system, especially in
primitive bone marrow cells.
3.5. MnP induces intracellular antioxidant defenses and NRF2
signaling
To further confirm the potential of the adaptive antioxidative
mechanism and explore which pathways are affected by MnP, we
performed an oxidative stress transcription factor (TF) activation
profiling array. The array includes the 16 most common consensus
DNA sequences of TF DNA-binding sites which respond to oxidative
stress. In this experiment, BMNCs were isolated from three groups of
five mice and treated with vehicle or 20 μM of MnP for 1 h in vitro.
Triplicate nuclear extracts from 5×105 flow cytometry sorted LK (Lin-
and ckit +) cells were used in the assay. As shown in Fig. 6A, MnP
significantly upregulated NRF2/ ARE and ETS (E twenty-six transcrip-
tion factors) TF binding activities by 3 and 2.8 times, respectively, more
than vehicle-treated. Nrf2 antioxidant response pathways play impor-
tant roles in cellular antioxidant defense. To confirm the elevation of
Nrf2 transactivation activity, we did quantitative PCR on mRNA
expressions of representative Nrf2 target genes at 1 h and 16 h MnP
treatments. The result shows that catalase (CAT), MnSOD, peroxir-
edoxin 1 (Prdx1), glutamate-L-cysteine liage (GCLC-L), glutamate-
cysteine ligase regulatory subunit (GCLM-L), NAD(P)H Quinone
Oxidoreductase (Nqo1), UCP1 and UCP3 were elevated at the 1 h
and/or 16 h MnP in vitro treatments (Fig. 6B & C) respectively.
Western blot analysis shows that the Nrf2 target proteins exemplified
by catalase, MnSOD, GSTp1 and UCP3 were elevated (Fig. 6D). The
results support our hypothesis that MnP acts as a pro-oxidant in bone
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Fig. 3. MnP increases HSC engraftment and multilineage differentiation by serial bone marrow transplantations (BMT). A. Donor cells were isolated from 60-day saline or MnP in vivo
treated mice (n=6 for vehicle or MnP treatment). B. The donor cells were in vitro treated with vehicle or 20 μMMnP (MnP) for 16 h (n=6 vehicle or MnP treatment). Percentage of LSK
cells of the donor-derived (Ly5.2) bone marrow nucleated cells (BMNCs) in the recipients (n=6 for each treatment) was analyzed by flow cytometry. (i) The results at 16 weeks post the
first BMT. (ii) The results at 16 weeks post the second BMT. (iii) The results at 16 weeks post the third BMT. Data represent the mean+SD.
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marrow cells which consequently stimulates the intracellular antiox-
idative defense system. The results are also consistent with evidence
that Nrf2 signaling plays important roles in regulating stem cell
physiology [29,30,31]. The UCP3 elevation is consistent with our data
that MnP suppresses mitochondrial function in bone marrow cells.
ETS transcription factors comprising more than 26 genes in
vertebrates have been implicated in regulation of hematopoiesis. The
hallmark ETS factor involved in hematopoiesis is encoded by the PU.1
gene that regulates the expression of multiple genes for different
lineages during normal hematopoiesis and also directs homing and
long-term engraftment of hematopoietic progenitors to bone marrow
[32]. Additionally, several other ETS factors, including FLI1, TEL/
ETV6 and a series of recently discovered ETS-Related Genes (ERG),
have been shown to play critical roles at various levels of hematopoiesis
[33]. Our oxidative gene transcription factor array shows that ETS
transcription activity was elevated by MnP treatment (Fig. 6A), and our
preliminary studies show that the expression of several ERG genes was
altered upon MnP treatment (unpublished data). The significance of
ETS target genes in the regulation of ROS is interesting and will be a
topic of future investigation.
4. Discussion
Redox homeostasis plays pivotal roles in regulating the self-renew-
al, differentiation, and genomic stability of stem cells. SOD enzymes
involved in dismutation of superoxide anion to hydrogen peroxide act
as the first line of defense against disturbance of ROS homeostasis.
Mitochondria are the main site of superoxide production. Therefore,
MnSOD, located in mitochondria, is the primary antioxidant enzyme
that removes superoxide radicals generated in the mitochondria. Our
CAFC and CFU assays and serial BMT result show that colony forming
capability and engraftments / multilineage differentiation are increased
in cells treated with MnP. This observation is consistent with a recent
study showing that undifferentiated embryonic stem cells (ESCs)
expressed an increased amount of mitochondrial MnSOD compared
to their differentiated counterpart [34]. We therefore hypothesized that
SOD mimetics play roles in regulating bone marrow HSPC proliferation
and differentiation through regulation of ROS.
Our observation that MnP may act as a transient pro-oxidant, as
indicated by DCF and Nrf2 activation assays, is unexpected and merits
careful consideration. DCF assay detects numerous reactive oxygen
species including hydrogen peroxide, thiyl radicals, nitric oxide,
nitrogen dioxide, and peroxynitrite [35]. At the 2 h in vitro treatment
with MnP, we detected an increase in total ROS in all three different
lineages of hematopoietic cells compared to vehicle controls. Together
with our quantitation PCR and Western blots confirmation of the Nrf2
pathway activation, our results support the hypothesis that MnP acts as
a mild pro-oxidant. However, in the 60-day MnP in vivo- treated and
MnSOD transgenic bone marrow cells, we did not detect ROS change.
Furthermore, we did not detect any significant changes in the GSH/
GSSG redox couple on MnP- treated LSKs at 2 h and 16 h. These
results suggest that the ROS increase in the in vitro- treated cells did
not disturb the GSH/GSSG redox homeostasis. Our examinations of
the antioxidant capacity of different lineage cells show clearly that the
more primitive LSK cells are in a more reduced physiological status and
have a much stronger capacity to clear H2O2 compared to more mature
cells. This evidence strengthens our hypothesis that, acting as a mild
pro-oxidant, MnP activates such endogenous oxidative defense systems
as the Nrf2 pathway, thereby not only regulating intracellular redox
homeostasis but possibly also affecting bone marrow HSPC regulation.
Nrf2 signaling is one of the best-characterized defense mechanisms
that acts against oxidative insults. It controls the basal and induced
Fig. 4. MnP inhibits mitochondrial oxidative phosphorylation and ATP production in LSK. A. The raw data of oxygen consumption rate (OCR) of Seahorse analysis on LSK cells. LSK
cells were isolated and treated with vehicle or 20 μMMnP (MnP) for 2 h at 37 °C in 5% O2 incubator. The cells were then harvested, immunostained, flow cytometry sorted, and seahorse
analyzed in the presence of the mitochondrial inhibitors (Oligomycin, 1 μg/ml, FCCP 1 μM, or Rotonone 1 µM and Antimycin 2 µM). B. The quantitation of basal, ATP-linked, the
maximum, and the reserve capacity of oxygen consumption rate of panel A (n=3). C. The freshly isolated bone marrow cells were treated with either vehicle or 20 μMMnP (MnP) for 1 h,
immune-stained and sorted. Equal amounts of cell lysate of LSK and MyPro cells were analyzed for ATP production cells (n > 6). Data represent the mean+SD of at least three
independent experiments.
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expression of an array of antioxidant genes that regulate physiological
and pathophysiological oxidative responses. Evidence shows that Nrf2
also plays a pivotal role in regulation of stem cells. A recent report
shows that Nrf2 is highly expressed in undifferentiated HSCs compared
with differentiated cells. The same study also shows that a reduction of
Nrf2 activity enhances the differentiation of HSCs and that the reversal
of Nrf2 knockdown increases pluripotency [29]. Despite the function of
transactivation of downstream antioxidant genes, the role of Nrf2 on
HSC maintenance can also be independent of cellular ROS concentra-
tion [30]. As reported, Nrf2 directly binds to ARE in the promoter
region of Cxcr4, which is essential for the maintenance of the quiescent
HSC pool [31]. Thus, it is possible that MnP, as a mild pro-oxidant and
a ROS regulator, activates the intracellular oxidative defense system
through Nrf2 signaling, leading to Nrf2- dependent and -independent
enhancement of bone marrow stem cells, as illustrated in Fig. 7.
It has been suggested that different types of ROS molecules might
provide a fine mechanism for tuning redox signaling to control the
delicate balance among cell growth, proliferation, and differentiation of
HSCs [36]. A reduction in MnSOD activity favors proliferation of
MEFs, while induction of MnSOD activity facilitates a proliferation of
cells transitioning into quiescence [37]. MnSOD -/- MEFs failed to exit
from the proliferative cycle and showed increased cyclin D1 and cyclin
B1 accumulation compared to MnSOD +/+ MEFs. Overexpression of
MnSOD in MnSOD +/- MEFs suppresses O2
−., decreases cyclin B1, and
facilitates cell transit into quiescence. Our finding is in agreement with
the hypothesis that MnSOD, by catalyzing O2
-. to H2O2, switches the
superoxide-signaling pathway that regulates proliferation to a hydro-
gen peroxide-signaling pathway that supports quiescence, demonstrat-
ing that the roles and functions of ROS in stem cells are diverse and
context dependent.
A recent report demonstrates that under oxidative stress, increased
ROS production is counteracted by Nrf2-dependent transcriptional
upregulation of mitochondrial uncoupling protein 3, UCP3, via Nrf2
binding to the ARE site on the UCP3 promoter [38]. H2O2 increases the
UCP3-mediated proton leak, and consequently decreases the produc-
tion of superoxide from the electron transport chain [39]. Nrf2 is also
known to be an important player in the maintenance of mitochondrial
homeostasis through regulation of mitochondrial membrane potential,
OXPHOS and ATP production [40]. The reports are in agreement with
our data showing that MnP increases UCPs through elevated Nrf2
signaling and, in turn or independently, decreases mitochondrial
function that further reduces endogenously generated ROS.
SOD mimetics, by their structures, act more as redox regulators
than simple antioxidants. They can be an oxidant or a reductant inside
cells and have an antioxidative impact only if H2O2 is efficiently
removed [18].
(H2O)2Mn
IIIP5+ +O2
·- < === > (H2O)Mn
IIP4+ +O2 +H2O, kred(O2
·-)
(H2O2)Mn
IIP4+ +H2O+2H
+ +O2
·- < === > (H2O)2Mn
IIIP5+ + H2O2,
kox(O2
·-)
This feature gives them the potential to leverage the physiological
properties of cells that have different antioxidant capacities to regulate
intracellular ROS homeostasis. As mentioned above, SOD mimetics not
only have been reported to provide radioprotection in animal models,
they have been shown to be radio- and chemo- sensitizers, as they
radio- sensitize treatments in head and neck tumors in mice [19], brain
glioma mouse model [41] and a 4T1 mouse breast cancer xenograft
Fig. 5. ROS status in different lineage cells physiologically and after treatment with vehicle or MnP or H2O2. A. BMNCs were isolated and treated in vitro with vehicle or 20 μM MnP
(MnP) or 20 μMMnP+Catalase (CAT) at 4000U/ml/100,000 cells for 2 h at 37 °C. The cells were immunostained at 4 °C, incubated with H2DCFDA, DCFDA or H2DCFDA +/- CAT, for
15 min at 37 °C and flow cytometry analyzed. The mean fluorescence intensities (MFIs) in Lin+, MyPro and LSK cells are presented (n > 6). B. BMNCs were isolated from 60-day saline
or MnP treated mice (n=8) and incubated with H2DCFDA or DCFDA. C. BMNCs were isolated from wild- type (WT) or MnSOD2 transgenic mice (SOD TgH) (n=6). D. Freshly isolated
BMNCs were treated in vitro with vehicle or MnP for 2 h (left panel) or 16 h (right panel). 2×104 of LSKs were HPLC analyzed. The ratios of 2xGSH/GSSG are presented. E. The ratio of
2xGSH/GSSG on the freshly isolated LSK or MyPro cells. F·H2O2 treatment of LSK, MyPro and Lin+ cells. The BMNCs were isolated, then incubated with H2DCFDA or DCFDA for
20 min and with different concentrations of H2O2 for 15 min at 37 °C, washed and flow cytometry analyzed. The fold changes labeled above the bars are calculated vs. the 0 μMH2O2
treatments. Data are represented as the means+SD.
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model [42].
It is worth mentioning that Weimin Miao and his colleagues have
recently reported that overexpression of MnSOD by retroviral trans-
duction exhibited an insignificant effect on long-term engraftment of
transplanted HSCs. However, overexpression of catalase has a sig-
nificant beneficial effect [43]. In their paper, the authors report that the
product of MnSOD, H2O2, can act as a pro-oxidant and therefore could
be damaging stem cells unless the cells were co-transfected with
catalase to remove H2O2. Indeed, the result is in agreement with our
data that MnP acting as a pro-oxidant increases Nrf2-mediated up
regulation of catalase and other antioxidative enzymes. The adaptive
effect could be the reason that stem cell function was enhanced in our
study. In the same study, the authors also demonstrated that admin-
istration of a MnSOD plasmid and lipofectin complex (MnSOD-PL) is
protective against radiation-induced injury of stem cells without
concurrent overexpression of catalase. This finding also supports the
radio-protective effect of MnP reported in other studies.
Our results suggest that MnP in bone marrow cells reduces O2•- to
H2O2. The elevated H2O2 activates intracellular Nrf2 signaling, which
activates the production of antioxidant enzymes. MnP through Nrf2-
dependent up-regulation of UCPs or independently reduces mitochon-
drial function and ATP synthesis. The adaptive responses of both
decreased mitochondrial OXPHOS and increased intracellular antiox-
idant defenses lead to a concomitant decrease in ROS levels, which
contributes to the improvement of stem cell maintenance. In addition,
MnP, via an Nrf2-independent regulation of stem cells and activation
of the ETS system, may also contribute to the increase in stem cell
production and function (Fig. 7).
5. Conclusions
This study is the first to report two novel findings: A mild pro-
oxidant could induce stem cell function through adaptive responses
that include suppression of mitochondrial respiration and stimulation
of endogenous antioxidant defenses. The bone marrow stem cells and
early progenitor cells have a higher capacity to remove H2O2 than
mature cells have. MnP has been used in clinical trials for its radiation-
protection during cancer treatment. It has been reported that MnP acts
as a sensitizer for cancer treatment in animals. The finding that MnP
enhances the LSK cell pool augments the application of MnP as a
potential novel agent clinically. Importantly, our results contribute to a
better understanding of stem cell regulation by ROS. Numerous studies
in the past decade have uncovered the importance of redox signaling to
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the biology of stem cells. However, the differential effect of different
ROS molecules on stem cell regulation remains unclear and warrants
further in-depth studies. It also would be interesting to investigate
further the properties of MnP on bone marrow stem cells under
pathological conditions where replenishment of hematopoietic cells is
urgently needed.
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